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Background: It is not established whether sex influences outcome and safety following intravenous thrombolysis
(IVT) in acute stroke. As a significant imbalance exists between the baseline conditions of women and men,
regression analysis alone may be subject to bias. Here we aimed to overcome this methodical shortcoming by
balancing both groups using coarsened exact matching (CEM) before evaluating outcome.
Methods: From our local prospective stroke database we analyzed consecutive patients who suffered anterior
circulation stroke and received IVT from 1998 to 04/2013 (n = 1391, 668 female, 723 male). Data were preprocessed
by CEM, balancing for age, NIHSS, lesion side, hypertension, diabetes, atrial fibrillation, smoking, coronary heart
disease, and previous stroke, which yielded a matched cohort of 502 women and 436 men (n = 938). Outcome was
estimated by adjusted binomial logistic regression analysis incorporating matched weights.
Results: No effect of sex was seen to predict good outcome (OR 1.04, CI 0.76–1.43) or mortality (OR 1.13, CI 0.73–1.73).
However, female sex was a strong independent predictor of symptomatic intracerebral hemorrhage (sICH – ECASS-II
definition, OR 3.62, CI 1.77-7.41) and fatal ICH (OR 4.53, CI 1.61-12.7).
Conclusion: In balanced groups, the two sexes showed comparable outcomes following IVT. A novel finding was the
higher rate of sICH and fatal ICH in women. In this analysis we also demonstrate how CEM can reduce multivariate
imbalance and thereby improve estimates, already in crude, but more importantly, in adjusted regression analysis.
Further investigations of multicentre data with improved analytical approaches that yield balanced sex-groups are
therefore warranted.
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It is still not established whether sex has an impact on
outcome in acute stroke patients who received intraven-
ous thrombolysis (IVT). Former studies reported mainly
equipoise in the 3-months outcome following IVT in
women compared to men [1-3], but also a disadvantage
for women was found [4]. Two studies found a greater in-
cidence of bleeding complications in men [1,2]. However,
all these studies have a critical bias in common. As sex is
a nature-determined factor, (primary) randomization is
obviously not possible. In addition, if covariates are very
different between the sexes, the results of regression* Correspondence: Lars.Kellert@med.uni-muenchen.de
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unless otherwise stated.analysis alone can be misleading [5-7]. To overcome these
issues in comparing the sexes, we improved the balance
within the groups in a first step by coarsened exact match-
ing (CEM) [8], thereby neglecting outcome and safety
variables. To account for the remaining bias in covariates
and to estimate outcome, we then performed adjusted
regression analysis. This two-step approach is less prone
to model misspecification and even more robust than are
results based on the full unmatched data set [7,9,10].Aims
Improve multivariate balance between the sexes using
coarsened exact matching (CEM) to investigate whether
IVT treated women differ from IVT treated men with
respect to outcome and safety.ral. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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From our local prospective stroke database we analyzed
clinical and imaging data of all consecutive patients who
received IVT from 1998 to 04/2013 (n = 1501). Our pro-
spective local stroke database was managed and this
study implemented according to the STrengthening the
Reporting of OBservational studies in Epidemiology
(STROBE) statement for reporting case–control studies
[11]. Data were collected as part of national and inter-
national quality-control programs. The retrospective
analysis of the data lacks any treatment influence and
therefore written informed consent and a formal ethical
approval from the local ethics committee of the Univer-
sity of Heidelberg was waived. We excluded from further
analysis 93 patients with posterior circulation stroke, 13
patients due to missing clinical follow-up, and 4 patients
who died before follow-up imaging. Therefore, 1391
patients comprised the unmatched cohort. Three-month
outcome was assessed either during an outpatient visit
or a telephone interview using the mRS. Good outcomes
were adjusted with respect to NIHSS score at presenta-
tion as previously described [12]: Presenting NIHSS
scores of 1 to 7 a mRS score 0 at follow-up, presenting
NIHSS scores of 8 to 14 mRS scores of 0 or 1, and pre-
senting NIHSS scores above 14 mRS scores of 0–2 were
counted as good outcome. Time to treatment was
defined as time from symptom onset to start of IVT.
Symptomatic intracerebral hemorrhage (sICH) was de-
fined according to the definition of the ECASS-II trial
[13]. Fatal ICH was defined as death caused most prob-
ably due to sICH following IVT. It has been shown
recently that it is preferable to treat missing data by
multiple imputation rather than listwise deletion in fur-
ther processing (matching, multiple regression analysis)
[14,15]. Therefore, Amelia II [16] for multiple imput-
ation (m = 10) was used to further process all (n = 1391)
instead of (only) 1126 patients. Covariates were imputed
as follows: statin use (4.5%), antithrombotics (3.7%), oral
anticoagulation (2.2%), thrombocytes (7.9%), systolic
blood pressure (15%), and diastolic blood pressure
(15.6%). Importantly, no nonlisted variables and no out-
come variables were imputed. As recommended, each
imputed data set was analyzed separately and combined
at the end [16]. Groups of baseline characteristics were
compared with the Student’s T-Test, the Mann–Whitney
U-Test, or the Fisher’s Exact Test, as appropriate, and
accounted for matched weights on matched group com-
parisons. In all statistical analyses, a p-value of 0.05 was
considered significant. The following variables were then
preprocessed using CEM: age, NIHSS, lesion side, hyper-
tension, diabetes, atrial fibrillation, smoking, coronary
heart disease, and previous stroke. The aim of matching
is not to estimate, but rather to find better balance in
the multidimensional distribution of covariates of thegroups. This in turn reduces the degree of dependence
on the estimation model of the outcome variable and
therefore diminishes bias [10]. In detail, the CEM
algorithm consists of three steps. First, desired variables
of all patients are coarsened temporarily. Second, all
patients of the initial cohort are sorted into strata on the
basis of their coarsened variables. Third, only patients
with strata containing at least one woman and one man
are kept; others are discarded. Additionally, a weighting
variable is generated to equalize the number of women
and men in one stratum. CEM is a matching method of
the class monotonic imbalance bounding [8]. This
means that reducing imbalance in the empirical distribu-
tion in one covariate has no effect on any other covari-
ates chosen for balancing, which represents a clear
advantage of CEM over other matching methods [17].
Of course, only observed variables are accounted for in
matching, and thus bias of omitted covariates cannot be
eliminated. For balance checking Iacus and colleagues
introduced the multivariate imbalance measure L1 [8].
Ranging from 0 to 1 - L1 is a relative magnitude depend-
ing on the data set and the selected covariates. The more
the two distributions overlap, the more L1 decreases and
trends to zero. The advantage of this two-step approach,
first performing a matching solution and then an out-
come estimation, is that it is more robust than, for
example, regression analysis alone and also insensitive to
selecting outcome model specifications arbitrarily, which
is a common potential bias source [7,9,10]. In a final
step, outcome was estimated by binomial logistic regres-
sion incorporating matched weights. Statistical analysis
was performed using R [18-20] and SPSS (SPSS Inc.,
21.0 for Windows).
Results
The unmatched group comprised 668 woman and 723
men (n = 1391). Women were older than men (75.3y vs.
68.8y, p < 0.001) and suffered from more severe strokes
according to NIHSS on admission (12 vs. 10, p < 0.001).
Time to treatment (TTT) was equal for the two groups
(140 min vs. 140 min, p = 0.615). In the female group
hypertension (83.1% vs. 78.1%, p = 0.021) and atrial fib-
rillation (40.7 vs. 25.6%, p < 0.001) were observed more
often, while current smoking (9.6% vs. 20.2%, p < 0.001),
coronary heart disease (17.1% vs. 26.0%, p < 0.001) and
hyperlipidemia (29.2% vs. 35.4%, p = 0.014) were less
represented in women than in men. After improving
balance, 502 women and 436 men (n = 938) comprised
the matched cohort. Table 1 shows the baseline charac-
teristics of the unmatched and matched cohort in
detail. Unadjusted distribution of mRS for women and
men prior to and after matching is presented in Figure 1.
Multivariate imbalance measure L1 improved from 0.834
to 0.777.
Table 1 Baseline characteristics for sex in unmatched and matched cohort (Matched variables are marked bold)
Unmatched Matched
Female Male P Female Male P§
N 668 723 502 436
Age* 75.3 (12.1) 68.8 (12.7) <0.001 74.4 (11.0) 74.3 (10.9) 0.939
NIHSS† 12 (7; 17) 10 (6; 15) <0.001 12 (7; 17) 12 (6; 17) 0.506
Hemisphere, left‡ 402 (60.2%) 412 (57.0%) 0.231 317 (63.1%) 275 (63.1%) >0.999
Hypertension‡ 555 (83.1%) 565 (78.1%) 0.021 433 (86.3) 376 (86.3%) >0.999
Diabetes‡ 170 (25.4%) 188 (26.0%) 0.854 106 (21.1%) 92 (21.1%) >0.999
Atrial fibrillation‡ 272 (40.7%) 185 (25.6%) <0.001 185 (36.9%) 161 (36.9%) >0.999
Current smoker‡ 64 (9.6%) 146 (20.2%) <0.001 33 (6.6%) 29 (6.6%) >0.999
CHD‡ 114 (17.1%) 188 (26.0%) <0.001 67 (13.3%) 58 (13.3%) >0.999
Previous Stroke‡ 135 (20.2%) 155 (21.4%) 0.597 64 (12.7%) 56 (12.7%) >0.999
TTT [min]† 140 (105; 180) 140 (105; 180) 0.615 140 (105; 180) 140 (110; 180) 0.504
Hyperlipidemia‡ 195 (29.2%) 265 (35.4%) 0.014 142 (28.3%) 115 (26.3%) 0.557
Statin use‡ 137 (20.5%) 202 (27.9%) 0.001 103 (20.5%) 96 (22.0%) 0.576
Antithrombotics‡ 298 (44.6%) 340 (47%) 0.389 212 (42.2%) 216 (49.6%) 0.026
OAC‡ 44 (6.6%) 31 (4.3%) 0.074 27 (5.4%) 21 (4.7%) 0.767
Systolic BP [mmHg]† 160.6 (22.1) 159.1 (22.1) 0.202 161.5 (21.0) 160.3 (22.5) 0.408
Diastolic BP [mmHg]† 86.1 (16.0) 88.2 (15.1) 0.009 86.1 (15.6) 86.3 (15.5) 0.856
Glucose [mg/dl]† 121 (105; 148) 120(105; 147) 0.434 120 (105; 147) 121 (106; 144) 0.706
Platelet [count/nl]† 263 (215; 313) 233 (193; 283) <0.001 266 (216; 313) 234 (192; 277) <0.001
Numbers are mean (standard deviation) or median (25/75 interquartile range) or counts (percentages).
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In the unmatched cohort, sex was significantly associ-
ated with good outcome (178 women (26.6%), 232 men
(32.1%), p = 0.029) in the univariate, but not in the
multivariate analysis (Figure 2). A logistic regression
model to predict good outcome (139 women (27.7%),
124 men (28.3%), p = 0.827) in the matched cohort
showed no effect of sex but did find an independentFigure 1 mRS day 90 in (A) unmatched and (B) matched cohorts.negative effect of age (OR 0.95, CI 0.93–0.97, p < 0.001),
NIHSS (OR 0.94, CI 0.92–0.97, p < 0.001), TTT (OR 0.99,
CI 0.99–0.99, p = 0.003), sICH (OR 0.14, CI 0.03–0.51,
p = 0.002), current smoking (OR 0.49, CI 0.26–0.95,
p = 0.035), and diastolic blood pressure (OR 0.98, CI
0.97–0.99, p = 0.007) (Table 2).
Mortality
Univariate analysis of mortality (137 women (20.5%), 84
men (11.6%), p < 0.001) in the unmatched group showed
significant differences in sex, but the effect did not persist
in multivariate analysis. Independently associated with
mortality (93 women (18.5%), 61 men (13.9%), p = 0.064)
in the matched cohort were age (OR 1.09, CI 1.06–1.12,
p < 0.001), NIHSS (OR 1.10, CI 1.07–1.13, p < 0.001),
TTT (OR 0.99, CI 0.99–0.99, p = 0.003), sICH (OR 20.6,
CI 9.52–44.7, p < 0.001), glucose (OR 1.00, CI 1.00–1.01
p = 0.009), hypertension (OR 0.44, CI 0.21–0.90, p = 0.026),
and hyperlipidemia (OR 1.99, CI 1.10–3.61, p = 0.022).
Similarly to the unmatched cohort, a logistic regression
model to predict mortality in the matched cohort showed
no effect of sex (Table 2).
Figure 2 Influence of sex on (1) good outcome, (2) mortality, (3) sICH, and (4) fatal ICH in unmatched (rhombus) and matched (square)
cohorts performing crude (empty markers) and adjusted (filled markers) regression analysis.
Table 2 Adjusted* binomial logistic regression full model in the matched cohort for (1) good outcome, (2) mortality,
(3) sICH, and (4) fatal ICH
Good Outcome Mortality sICH Fatal ICH
OR (95% CI) P OR (95% CI) P OR (95% CI) P OR (95% CI) P
Sex 1.04 (0.76–1.43) 0.774 1.13 (0.73–1.73) 0.572 3.62 (1.77–7.41) <0.001 4.53 (1.61–12.7) 0.004
sICH 0.14 (0.03–0.51) 0.002 20.6 (9.52–44.7) <0.001
NIHSS 0.94 (0.92–0.97) <0.001 1.10 (1.07–1.13) <0.001 1.02 (0.98–1.07) ns 1.03 (0.96–1.09) ns
Age 0.95 (0.93–0.97) <0.001 1.09 (1.06–1.12) <0.001 0.97 (0.94–1.01) ns 1.01 (0.95–1.06) ns
TTT [min] 0.99 (0.99–0.99) 0.003 0.99 (0.99–0.99) 0.003 1.00 (1.00–1.00) ns 1.00 (1.00–1.00) ns
Diastolic BP [mmHg] 0.98 (0.97–0.99) 0.007 1.00 (0.99–1.02) ns 0.99 (0.97–1.02) ns 1.00 (0.97–1.03) ns
Current Smoker 0.49 (0.26–0.95) 0.035 1.26 (0.37–4.20) ns 0.07 (0.00–5.07) ns 0.21 (0.00–15.2) ns
Glucose [mg/dl] 0.99 (0.99–1.00) ns 1.00 (1.00–1.01) 0.009 1.00 (0.99–1.01) ns 1.00 (0.99–1.01) ns
Hyperlipidemia 0.79 (0.49–1.27) ns 1.99 (1.10–3.61) 0.022 1.21 (0.52–2.82) ns 0.85 (0.24–3.07) ns
Hypertension 1.21 (0.75–1.96) ns 0.44 (0.21–0.90) 0.026 3.03 (0.64–14.3) ns 0.49 (0.12–2.05) ns
Antithrombotics 0.76 (0.52–1.11) ns 1.29 (0.81–2.05) ns 2.13 (1.04–4.37) 0.040 3.76 (1.26–11.2) 0.018
Atrial fibrillation 0.84 (0.58–1.21) ns 1.10 (0.70–1.71) ns 1.04 (0.53–2.01) ns 1.48 (0.60–3.62) ns
CHD 0.69 (0.39–1.21) ns 1.73 (0.98–3.05) 0.055 0.91 (0.37–2.22) ns 1.39 (0.46–4.16) ns
Diabetes 0.99 (0.62–1.57) ns 0.77 (0.44–1.37) ns 2.01 (0.95–4.26) 0.070 1.32 (0.44–3.91) ns
Previous Stroke 0.83 (0.49–1.39) ns 1.35 (0.77–2.37) ns 1.91 (0.89–4.10) 0.097 2.02 (0.73–5.62) ns
OAC 1.58 (0.76–3.28) ns 1.63 (0.68–3.90) ns 0.11 (0.00–7.58) ns 0.26 (0.00–20.2) ns
Platelet [count/nl] 0.99 (0.99–1.00) ns 1.00 (0.99–1.00) ns 1.00 (0.99–1.00) ns 1.00 (0.99–1.00) ns
Hemisphere, left 0.83 (0.60–1.14) ns 1.19 (0.76–1.84) ns 0.62 (0.34–1.14) ns 0.66 (0.29–1.52) ns
Statin 0.95 (0.55–1.63) ns 0.74 (0.37–1.49) ns 0.61 (0.22–1.71) ns 0.80 (0.15–4.10) ns
*adjusted for NIHSS, lesion side, age, time to treatment (TTT), previous stroke, glucose, atrial fibrillation, hypertension, diabetes, hyperlipidemia, current smoker,
coronary heart disease (CHD), antithrombotics, oral anticoagulation (OAC), platelet count, diastolic blood pressure (BP) and statin use, and symptomatic
intracerebral hemorrhage (sICH, only in model 1 and 2).
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Sex was significantly associated with sICH (45 women
(6.7%), 24 men (3.3%), p = 0.004) in univariate and multi-
variate analysis in the unmatched cohort. Multivariate
analysis to predict sICH (37 women (7.4%), 11 men
(2.6%), p = 0.001) in the matched cohort found female
sex (OR 3.62, CI 1.77–7.41 p < 0.001) and antithrom-
botic treatment (OR 2.13, CI 1.04–4.37, p = 0.04) as the
only independent predictors (Table 2).
Fatal ICH
Sex was significantly associated with fatal ICH (23
women (3.4%), 8 men (1.1%), p = 0.003) in univariate but
not in the multivariate analysis in the unmatched cohort.
Multivariate analysis to predict fatal ICH (20 women
(4.0%), 5 men (1.2%) p = 0.008) in the matched cohort
found female sex (OR 4.53, CI 1.61–12.7, p = 0.004)
and antithrombotic treatment (OR 3.76, CI 1.26–11.2,
p = 0.018) as the only independent predictors (Table 2).
Discussion
To our knowledge this is the first time a balanced cohort
of women and men has been used to analyse the influ-
ence of sex on outcome and safety after IVT in acute
ischemic stroke. In these balanced groups 3-months out-
come and mortality following IVT was comparable be-
tween the two sexes. In addition, we report the novel
finding of increased bleeding complications in IVT-
treated women.
We substantially tried to remove bias from our analysis
of functional outcome. Saver and colleagues recently re-
ported that it is meaningful to perform a baseline severity-
adjusted endpoint analysis [12]. This adjustment may in
particular be meaningful in a sex-based analysis, since
NIHSS distributions may differ between the sexes, even if
they appear similar in mean. The presented results appear
to be in line with previous studies, which found no differ-
ences in functional outcome between the sexes evaluating
mRS ≤ 1 [1,3] and mRS ≤ 2 [2]. However, they are not dir-
ectly comparable, because of the adjustment chosen in
our analysis. One single centre study also used a baseline
severity adjustment evaluating mRS ≤ 2, but reported uni-
variate results on sex only, because temperature was the
main study focus [21].
Regarding mortality our results are in line with the
post-hoc analysis of the Canadian Alteplase for Stroke
Effectiveness Study [1], but contradict the previously
largest study on this topic [2]. Lorenzano et al. found a
higher mortality in women in univariate, but just the
opposite, higher mortality in men, after multivariate
adjustment. In our matched cohort, already univariate
analysis yielded non-significant differences between the
sexes (Figure 2), which were confirmed on additional
adjustment. A limiting factor for a comparison of study-cohorts here might be the difference in analysis, namely
different grades of multivariate balance and the differences
in adjusting confounders. One example when estimating
mortality is the consideration of sICH as a confounder.
On the one hand sICH was not usually included in regres-
sion analysis for mortality of previous studies, although it
is an established predictor for mortality [22,23]. Inclusion
of sICH in the mortality regression may be misleading
because mortality is also a part of the definition of sICH
according to ECASS-II (any hemorrhage leading to death).
However, on the other hand in our cohort female sex was
an independent predictor of sICH. Therefore we preferred
to include sICH in mortality regression analysis and thus
omit an important sex-related mortality bias.
Again, crude mortality estimation of the matched cohort
already gains more robust results that are not changed
significantly after adjustment in contrast to estimation
of the unmatched cohort. This demonstrates how re-
searchers, if CEM is applied before regression analysis,
may improve their estimates and how different study
models may be better comparable, even if models
slightly differ, because included confounders are chosen
differently (see also [10]).
With respect to bleeding complication following IVT,
female sex turned out to be the most important pre-
dictor for sICH and fatal ICH in our matched cohort.
Previous studies observed a higher rate of sICH in men,
reasoning that a higher incidence of antithrombotics and
the higher absolute doses of recombinant tissue plas-
minogen activator (rtPA) (due to body weight) in men
could account for this finding [2]. The intake of antith-
rombotics was lower in women in our cohort, thus
favouring lower rates of sICH. Unfortunately, body
weight was not consecutively registered, and therefore
we can only conjecture very likely that the absolute dose
of rtPA was higher in men. For the moment we are also
interpreting the observed higher rate of sICH in women
as being a single-centre phenomenon. However, external
validation by a centre-based analysis of multicentre data
including balanced sex cohorts should provide more
in-depth insight regarding sex dependency on sICH.
The major strength of this study is its unique analytical
approach, aiming to minimize the bias due to different
covariates between the sexes. Pre-matching by CEM
improves balance essentially and achieves more robust
inferences than an unmatched, full data set does. An
example of possible avoided bias is illustrated in Figure 2.
In unmatched data, both crude and adjusted analyses
either underestimate the effect (e.g., for sICH) or may give
misleading results (e.g., for fatal ICH). However, facilitat-
ing a pre-matched regression analysis sex proved to be a
strong independent predictor of fatal ICH in our cohort.
Because CEM is a relatively novel rather than a standard
approach we provide the reader with unmatched and
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able a direct comparison of the results.
In our matching, we also included an often overlooked
covariate: lesion side. By pathophysiological means, left
and right anterior circulation strokes are reflected differ-
ently in the most commonly used score (NIHSS), with
left-hemispheric strokes yielding higher scores but better
outcomes [24]. Not considering these matters can produce
a critical bias in determining outcome. This is the first
study comparing sexes in stroke thrombolysis to address
both the bias of side of lesion and baseline severity-
adjusted analysis when determining outcome.
Our study has several limitations: This is a retrospect-
ive analysis of prospectively collected data from a single
centre – external validation is needed. The matching
process is accompanied by an attempt to find a reason-
able compromise between the optimal match and the
maximum size of the cohort. With respect to sICH we
had no information regarding early infarct signs and we
cannot adjust for body weight and consecutive rtPA
dose. Our results are limited to patients eligible for
treatment with IVT. Thus factors influencing outcome
after stroke like older age and higher prestroke disability
as well as sociodemographic parameters were not inves-
tigated in detail. We did not refer to parameters which
are known to influence outcome after stroke like pre-
stroke mRS, stroke subtype, vessel occlusion, and vessel
recanalization. Outcome studies in stroke may be biased
due to “do not resuscitate”- orders. This objection may
therefore also be true for our cohort. In addition, there
was no control group without IVT treatment. Therefore,
we cannot conclude an absolute effect of IVT within
sexes but only between the two sexes in comparison.
Conclusion
In balanced groups, the two sexes show comparable out-
comes following IVT. Taken together with the novel
finding of higher rates of sICH and fatal ICH in women,
further investigation of multicentre data in balanced
groups is warranted. For observational data CEM seems
to be a useful pre-processing tool to reduce bias in esti-
mating outcome.
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